吉西他滨/NAB-甲酰胺与Anlotinib和PD-1抑制剂相结合的疗效和安全性，作为晚期胰腺癌的一线治疗
Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
影响因子:4.70000
分区:医学2区 / 药学2区 免疫学3区
发表日期:2024 Sep 30
作者:
Haonan Liu, Di Pan, Zhiyuan Yao, Hongmei Wang, Yuqi Li, Xiaobing Qin, Pengfei Qu, Juanjuan Tang, Zhengxiang Han
摘要
研究吉西他滨/NAB-甲酰胺（AG方案）的临床疗效和不良反应与Anlotinib和PD-1抑制剂结合在一起，作为晚期胰腺癌（PC）的一线治疗。52例患者的DATA。回顾性分析。根据治疗方案，将患者分为两组，其中包括化学疗法组的27例患者（AG方案）和合并治疗组的25例患者（AG方案与Anlotinib和PD-1抑制剂联合使用）。在两组之间比较了总生存期（OS），无进展生存期（PFS），客观反应率（ORR），疾病控制率（DCR）和不良反应。使用Kaplan-Meier方法绘制了这两组的存活曲线，并通过对数级测试比较两组之间的PFS和OS差异。进行了单变量和多元COX回归分析，以识别影响预后的独立危险因素。合并治疗组的中位OS和PFS明显长于化学疗法组的OS和PF（OS，12.8 vs. 7.9个月，P = 0.005; PFS，PFS，PFS，5.6 vs. 4.4个月，P = 0.003）。两组之间的ORR没有显着差异（32.0％vs. 25.9％，P = 0.629），并且在合并治疗组中的DCR明显好于化学疗法组（84.0％vs. 59.3％，P = 0.049）。在两组中，1-2级不良反应均占主导地位，并且没有发生与反应相关的不良死亡。
Abstract
To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer (PC).Data of 52 patients with advanced PC who were treated in the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) between August 2019 and March 2023 were retrospectively analyzed. According to the treatment regimen, patients were divided into two groups, including 27 patients in the chemotherapy group (AG regimen) and 25 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitors). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were compared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors influencing prognosis.The median OS and PFS in the combined treatment group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.9 months, P = 0.005; PFS, 5.6 vs. 4.4 months, P = 0.003). There was no significant difference in ORR between the two groups (32.0 % vs. 25.9 %, P = 0.629), and DCR in the combined treatment group was significantly better than that in the chemotherapy group (84.0 % vs. 59.3 %, P = 0.049). Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction-related deaths occurred.Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitors exhibited to have a higher efficacy for the first-line treatment of advanced PC, and the adverse reactions were also controllable.